New German study.
I expect that not many of us who started out with localized PCa were worrying about quality of life [QoL] ten or more years out. I know that I was more concerned about the immediate five years.
"Several therapies for localised prostate cancer (PC) are available; all yield similar survival rates. However, each therapy has significant side effects that can influence patients' health-related quality of life (HRQoL) in the long run."
"Long-term localised PC survivors formerly treated with a combination of RP {radical prostatectomy} and RT {radiotherapy} or with ADT {androgen deprivation therapy} report poorer HRQoL {health-related quality of life} and more symptoms than patients treated with either RP or RT alone."
-Patrick
ncbi.nlm.nih.gov/pubmed/310...
Eur J Cancer Care (Engl). 2019 May 2:e13076. doi: 10.1111/ecc.13076. [Epub ahead of print]
Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study.
Adam S1,2, Koch-Gallenkamp L3, Bertram H4, Eberle A5, Holleczek B6, Pritzkuleit R7, Waldeyer-Sauerland M8, Waldmann A8,9, Zeissig SR10, Rohrmann S2, Brenner H3,11,12, Arndt V1.
Author information
1
Unit of Cancer Survivorship, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
2
Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
3
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
4
Cancer Registry of North Rhine-Westphalia, Bochum, Germany.
5
Bremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
6
Saarland Cancer Registry, Saarbrücken, Germany.
7
Schleswig-Holstein Cancer Registry, Lübeck, Germany.
8
Hamburg Cancer Registry, Hamburg, Germany.
9
Institute of Social Medicine and Epidemiology, University Lübeck, Lübeck, Germany.
10
Cancer Registry of Rhineland-Palatinate, Mainz, Germany.
11
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
12
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
OBJECTIVE:
Several therapies for localised prostate cancer (PC) are available; all yield similar survival rates. However, each therapy has significant side effects that can influence patients' health-related quality of life (HRQoL) in the long run.
METHODS:
The study sample included 911 survivors with localised PC, 5-15 years post-diagnosis who were identified from the population-based CAESAR + study in Germany. HRQoL was assessed using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. The association between type of therapy and HRQoL was assessed with multivariable linear regression and global F-test adjusting for age, time since diagnosis and comorbidities.
RESULTS:
Overall, survivors treated with radical prostatectomy (RP) or radiotherapy (RT) alone reported the best HRQoL and the lowest symptom burden. Conversely, survivors treated with androgen deprivation therapy (ADT) (& RP/RT) or RP & RT (in combination) reported the worst HRQoL and the highest symptom burden. Significant differences among treatment groups in HRQoL were found for global health status (p = 0.041), social functioning (p = 0.007), urinary symptoms (p = 0.035), bowel symptoms (p = 0.017) and hormonal treatment-related symptoms (p < 0.001) among other symptoms.
CONCLUSIONS:
Long-term localised PC survivors formerly treated with a combination of RP and RT or with ADT report poorer HRQoL and more symptoms than patients treated with either RP or RT alone.
© 2019 John Wiley & Sons Ltd.
KEYWORDS:
health-related quality of life; prostate cancer; therapy; well-being
PMID: 31050091 DOI: 10.1111/ecc.13076